Chronic Lymphocytic Leukemia (CLL) is a blood cancer that affects white blood cells and can hinder the body's ability to fight infection. CLL Extended 4 is an advanced diagnostic test that utilizes Flow Cytometry (FCM), Karyotyping, and Fluorescence In Situ Hybridization (FISH) to analyze cells affected by CLL. It is specifically designed to identify genetic markers and chromosomal abnormalities such as 17p deletion, ATM deletion (11q), Trisomy 12, and Del13q, which are critical in determining the severity and management of CLL.
Flow Cytometry helps to characterize the cells, Karyotyping examines the number and structure of chromosomes, and FISH focuses on the detection of DNA sequences, including the genetic markers mentioned above. Understanding the genetic aspects of leukemia cells is essential for determining the prognosis and tailoring treatment plans.
Test NameCLL Extended 4: FCM CLL Panel and Karyotyping and FISH For 17p, ATM Del, Trisomy 12, and Del13q
Sample TypeBlood/bone marrow
Preparations RequiredNo fasting is required. Inform your doctor of any medications or supplements you are taking.
Report Time12 days
What is the CLL Extended 4 test?
The CLL Extended 4 test is a comprehensive diagnostic procedure that uses Flow Cytometry, Karyotyping, and FISH to analyze and detect genetic markers and chromosomal abnormalities in cells affected by Chronic Lymphocytic Leukemia, including 17p deletion, ATM deletion, Trisomy 12, and Del13q.
Why are 17p deletion, ATM deletion, Trisomy 12, and Del13q significant?
These genetic markers are associated with various forms and prognoses of CLL. For example, the 17p deletion is linked to a more aggressive form of CLL and a poor response to standard chemotherapy. Knowing the presence of these markers can help doctors create a more customized treatment plan.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
If you have been diagnosed with CLL, the CLL Extended 4 test provides critical information regarding the genetic makeup of the leukemia cells. This information is vital for understanding the severity of the disease and for determining the most effective treatment strategy.
No fasting is required for this test.
The frequency of the test depends on various factors including the stage of the disease, response to treatment, and your doctor’s recommendations.
This test measures the properties and genetic characteristics of CLL cells, including chromosomal abnormalities such as 17p deletion, ATM deletion, Trisomy 12, and Del13q.
By identifying the chromosomal abnormalities and genetic markers, this test allows doctors to understand the aggressiveness of the disease and to design a more effective treatment plan tailored to your specific form of CLL.
In normal cells, the 17p deletion, ATM deletion, Trisomy 12, and Del13q are not present. Their presence in CLL cells indicates chromosomal abnormalities.
If the test results are abnormal, you should consult a hematologist or oncologist, who specializes in blood cancers.
The levels detected can be influenced by the progression of CLL, previous treatments, and other genetic or environmental factors.
You should inform your doctor of all medications and supplements you are taking as they may have an impact on the test results.
There are no known ways to change genetic markers in CLL cells. Treatment and management focus on targeting the abnormal cells and managing symptoms.
Flow Cytometry is essential for the characterization of CLL cells. It helps in distinguishing between various types of cells based on their properties, which is crucial in understanding the nature of the leukemia cells.
Karyotyping is a laboratory technique that looks at the number and structure of an individual’s chromosomes. In CLL, it is used to detect abnormalities in chromosomes that can affect the behavior of the leukemia cells.
It's important to understand that Chronic Lymphocytic Leukemia is a complex disease, and the CLL Extended 4 test is instrumental in obtaining a detailed picture of the genetic aspects of this condition. Knowing the specific chromosomal abnormalities present in CLL cells can significantly impact the management and treatment decisions. By combining the results of this test with other clinical information and consulting with your doctor, a more targeted and effective treatment plan can be developed for managing CLL. It's essential to discuss any concerns or questions you may have with your doctor.
CLL Extended 4 (FCM CLL Panel and Karyotyping and FISH For 17p and ATM Del and Trisomy 12 and Del13q)
